Liver stiffness measurement as an alternative to fibrotic stage in risk assessment of hepatocellular carcinoma incidence for chronic hepatitis C patients

2013 ◽  
Vol 33 (5) ◽  
pp. 756-761 ◽  
Author(s):  
Hsin-Ming Wang ◽  
Chao-Hung Hung ◽  
Sheng-Nan Lu ◽  
Chien-Hung Chen ◽  
Chuan-Mo Lee ◽  
...  
2008 ◽  
Vol 134 (4) ◽  
pp. A-795
Author(s):  
Ryota Masuzaki ◽  
Ryosuke Tateishi ◽  
Haruhiko Yoshida ◽  
Eriko Goto ◽  
Takahisa Sato ◽  
...  

Medicine ◽  
2017 ◽  
Vol 96 (46) ◽  
pp. e8621 ◽  
Author(s):  
Mohammed Tag-Adeen ◽  
Mohamed Alsenbesy ◽  
Ali Abdelrahman Ghweil ◽  
M. Ali Hussein Abd Elrazek ◽  
Elsayed A. Elgohary ◽  
...  

PLoS ONE ◽  
2017 ◽  
Vol 12 (9) ◽  
pp. e0184404 ◽  
Author(s):  
Ana Zaida Gomez-Moreno ◽  
Daniel Pineda-Tenor ◽  
Maria Angeles Jimenez-Sousa ◽  
Juan Jose Sánchez-Ruano ◽  
Tomas Artaza-Varasa ◽  
...  

2016 ◽  
Vol 25 (3) ◽  
pp. 331-335 ◽  
Author(s):  
Giovanna Ferraioli ◽  
Laura Maiocchi ◽  
Raffaella Lissandrin ◽  
Carmine Tinelli ◽  
Annalisa De Silvestri ◽  
...  

Background & Aims: Noninvasive assessment of liver stiffness has been increasingly used to evaluate fibrosis instead of liver biopsy, especially in patients with chronic viral hepatitis. The aim of this study was to assess the performance in staging liver fibrosis of the updated ElastPQ® technique (EPIQ7 ultrasound system, Philips Healthcare, Bothell, WA, USA) in the “real life” setting by using the FibroScan as the reference standard and to understand whether the use of the quality criteria improves the performance of the technique. Methods: This was a cross-sectional study: 278 patients affected by chronic hepatitis C referred for liver stiffness measurement with the FibroScan® 502 Touch device (Echosens, Paris, France) underwent measurements also with the ElastPQ® technique. For the assessment of significant fibrosis (F≥2), advanced fibrosis (F≥3) and cirrhosis (F=4), respectively, we used the cutoffs of 7.0, 9.5 and 12.0 kPa. The diagnostic performance of ElastPQ® was assessed using the area under the ROC (AUROC) curve analysis and was evaluated overall and for cases with (a) 10 measurements and IQR/M≤30%, (b) 5 measurements and IQR/M ≤30%, (c) 10 measurements and IQR/M>30%, (d) 5 measurements and IQR/M>30%. Results: The optimal cutoffs of ElastPQ® for significant fibrosis, advanced fibrosis and cirrhosis were 6.43, 9.54 and 11.34 kPa, respectively. For measurements with an IQR/M≤30%, there was no statistically significant decrease in sensitivity between 10 and 5 measurements (p=0.26, p=0.09, p=0.71, for F≥2, F≥3, and F=4, respectively). Conclusion: The ElastPQ® technique is reliable and accurate for staging liver fibrosis. The number of measurements does not affect the performance. Abbreviations: ALP: alkaline phosphatase; ALT: alanine aminotransferase; AST: aspartate aminotransferase; AUROC: area under the ROC curve; BMI: body mass index; GGT: gamma-glutamyl transferase; LR: likelihood ratio; LSM: liver stiffness measurement; pSWE: point shear wave elastography; ROC: receiver operating characteristic; VCTE: vibration controlled transient elastography; VTQ®: virtual touch quantification.


2008 ◽  
Vol 42 (7) ◽  
pp. 839-843 ◽  
Author(s):  
Ryota Masuzaki ◽  
Ryosuke Tateishi ◽  
Haruhiko Yoshida ◽  
Hideo Yoshida ◽  
Shinpei Sato ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document